{"product_id":"9781041231042","title":"Biological Drugs Volume 1 Development and Manufacturing","description":"\u003ch3\u003eDrugs and the Pharmaceutical Sciences\u003c\/h3\u003e\u003ch1\u003eBiological Drugs Volume 1\u003c\/h1\u003e\u003ch2\u003eDevelopment and Manufacturing\u003c\/h2\u003e\u003ch3\u003eSarfaraz K. Niazi\u003c\/h3\u003e\u003cdiv\u003e\u003cb\u003eScience \/ Biotechnology\u003c\/b\u003e\u003c\/div\u003e\u003cbr\u003e\u003cdiv\u003e\n\u003cp\u003eBiological drugs have revolutionized modern medicine, providing highly effective therapies for cancer, autoimmune diseases, genetic disorders, infectious diseases, and many other serious conditions. Their successful development, however, requires mastery of complex scientific principles, advanced manufacturing technologies, and an increasingly demanding global regulatory environment. This volume provides a comprehensive, practical guide to the development of both innovative biological products and biosimilars, covering every stage from product design and process development to manufacturing, quality assurance, regulatory submission, and commercialization.\u003c\/p\u003e\n\u003cp\u003eDrawing upon decades of scientific, industrial, and regulatory experience, the book explains how to establish efficient development strategies that reduce time, cost, and technical risk without compromising product quality or regulatory compliance. Numerous examples of electronic Common Technical Document (eCTD) submissions, development plans, manufacturing workflows, and regulatory documentation illustrate internationally accepted best practices and demonstrate how sound scientific principles can be translated into successful product development.\u003c\/p\u003e\n\u003cp\u003eComprehensive appendices summarize the regulatory dossiers and development pathways for virtually every major class of approved biological drugs, providing practical guidance for selecting appropriate development strategies and preparing scientifically justified submissions. Particular emphasis is placed on distinguishing essential regulatory expectations from unnecessary studies and common misconceptions that frequently increase development costs and delay market entry.\u003c\/p\u003e\n\u003cp\u003eCombining scientific depth with practical implementation, this volume serves as an authoritative reference for scientists, engineers, manufacturers, regulatory professionals, biotechnology entrepreneurs, and graduate students engaged in the research, development, manufacture, and approval of biological medicines worldwide.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eKey Features\u003c\/b\u003e\u003c\/p\u003e\n\u003cul\u003e \u003cli\u003eOutlines the history of technology and evolution of biological drugs, emphasizing the trends in the changes expected over the next two decades.\u003c\/li\u003e \u003cli\u003eDescribes the development of novel biological drugs, types of drugs, their mode of action, the hurdles in identifying and developing them.\u003c\/li\u003e \u003cli\u003eCreates practical manufacturing processes with novelty in mind; for example, recombinant may soon be replaced by cell-free or mRNA? Detailed discussions of all technologies are provided.\u003c\/li\u003e \u003cli\u003eDiscusses establishment of GMP-compliant manufacturing, from facility design to qualification with emphasis on multiple-use options.\u003c\/li\u003e \u003cli\u003eProvides examples of classes of biological drugs from therapeutic proteins to vaccines and gene therapies as well as examples of eCTDs for over 50 biological drugs.\u003c\/li\u003e \u003c\/ul\u003e\n\u003c\/div\u003e\u003cdiv\u003e\n\u003cp\u003e\u003cb\u003eProfessor Sarfaraz K. Niazi\u003c\/b\u003e is an internationally recognized authority in biological drugs, biosimilars, bioprocess technology, and regulatory science. He is the inventor or co-inventor on more than 200 U.S. patents, author of more than three dozen scientific books, and has published over 200 peer-reviewed papers. His work has contributed to the development and regulatory approval of numerous biological products while advancing global policies for biosimilars and biopharmaceutical development.\u003c\/p\u003e\n\u003cp\u003eProfessor Niazi has advised leading regulatory authorities, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), as well as the United States Senate, the White House, and governments worldwide on improving access to affordable biological medicines. A member of the National Inventors Hall of Fame, he has delivered more than 500 invited lectures internationally and continues to advance research in biological drugs, novel therapeutics, and regulatory innovation. He lives in Deerfield, Illinois, USA.\u003c\/p\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublication Date: \u003c\/td\u003e\n\u003ctd\u003e23 February 2027\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublisher: \u003c\/td\u003e\n\u003ctd\u003eCRC Press\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImprint: \u003c\/td\u003e\n\u003ctd\u003eCRC Press\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eISBN-13: \u003c\/td\u003e\n\u003ctd\u003e9781041231042\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormat: \u003c\/td\u003e\n\u003ctd\u003eHardback\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePage Count: \u003c\/td\u003e\n\u003ctd\u003e352\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e","brand":"CRC Press","offers":[{"title":"Default Title","offer_id":63772857893004,"sku":"9781041231042","price":252.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/lateknightbooks.com\/products\/9781041231042","provider":"Late Knight Books and Services, LLC","version":"1.0","type":"link"}